A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy

NMR in Biomedicine

Volumn 24, Issue 9, 2011, Pages 1169-1180

  Koh, Tong San ^a,b,c   Thng, Choon Hua ^a,b   Hartono, Septian ^a,c   Tai, Bee Choo ^d   Rumpel, Helmut ^e   Ong, Ai Bee ^e   Sukri, Norita ^e   Soo, Ross A ^e   Wong, Chuing Ing ^e   Low, Albert S C ^f   Humerickhouse, Rod A ^g   Goh, Boon Cher ^d  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

^g ABBOTT LABORATORIES   (United States)

Author keywords

Anti angiogenic drug trial; Biomarker; Dynamic contrast enhanced MRI

Indexed keywords

ANTI-ANGIOGENIC DRUG TRIAL; ANTI-ANGIOGENIC THERAPY; COMPARATIVE STUDIES; CONTRAST-ENHANCED; DCE-MRI; DISTRIBUTED-PARAMETER MODEL; DYNAMIC CONTRAST-ENHANCED MRI; INTRAVASCULAR; KAPLAN-MEIER; KINETICS MODELS; PHASE I; POST TREATMENT; RECEIVER OPERATING CHARACTERISTICS; TRACER KINETICS;

BIOMARKERS; DYNAMIC ANALYSIS; KINETICS; TUMORS;

DRUG THERAPY;

GADODIAMIDE; GADOLINIUM PENTETATE; LINIFANIB;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BLADDER TUMOR; BREAST CANCER; CANCER GROWTH; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; ENDOMETRIUM SARCOMA; FEMALE; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; KIDNEY TUMOR; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NERVE SHEATH TUMOR; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; HUMANS; INDAZOLES; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054064909     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1680     Document Type: Article

References (25)

1. Galbraith SM. MR in oncology drug development. NMR Biomed. 2006; 19: 681-689.
2. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2002; 15: 154-163.
3. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin. Cancer Res. 2007; 13: 770s-776.
4. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002; 62: 3408-3416.
5. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 2003; 21: 2831-2842.
6. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 2003; 21: 4428-4438.
7. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP. Dynamic Contrast-Enhanced Magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I Studies. J. Clin. Oncol. 2003; 21: 3955-3964.
8. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. 2005; 23: 4162-4171.
9. Mross K, Drevs J, Muller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 2005; 41: 1291-1299.
10. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee TY, Mayr NA, Parker GJM, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J. Magn. Reson. Imaging 1999; 10: 223-232.
11. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat. Biotech. 2001; 19: 1029-1034.
12. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003; 111: 1287-1295.
13. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
14. Koh TS, Cheong LH, Hou Z, Soh YC. A physiologic model of capillary-tissue exchange for dynamic contrast-enhanced imaging of tumor microcirculation. IEEE Trans. Biomed. Eng. 2003; 50: 159-167.
15. Cheong DLH, Lim TCC, Koh TS. Dynamic contrast-enhanced CT of intracranial meningioma: comparison of distributed and compartmental tracer kinetic models-initial results. Radiology 2004; 232: 921-930.
16. Bisdas S, Donnerstag F, Berding G, Vogl TJ, Thng CH, Koh TS. Computed tomography assessment of cerebral perfusion using a distributed parameter tracer kinetics model: validation with H2(15)O positron emission tomography measurements and initial clinical experience in patients with acute stroke. J. Cereb. Blood Flow Metab. 2007; 28: 402-411.
17. Koh TS, Thng CH, Lee PS, Hartono S, Rumpel H, Goh BC, Bisdas S. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced mr imaging with dual-input two-compartment tracer kinetics model. Radiology 2008; 249: 307-320.
18. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei R, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang Y, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006; 5: 995-1006.
19. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh BC. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J. Clin. Oncol. 2009; 27: 4718-4726.
20. Wang HZ, Riederer SJ, Lee JN. Optimizing the precision in T1 relaxation estimation using limited flip angles. Magn. Reson. Med. 1987; 5: 399-416.
21. Brookes JA, Redpath TW, Gilbert FJ, Needham G, Murray AD. Measurement of spin-lattice relaxation times with FLASH for dynamic MRI of the breast. Br. J. Radiol. 1996; 69: 206-214.
22. Zhang JL, Koh TS. On the selection of optimal flip angles for T1 mapping of breast tumors with dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans. Biomed. Eng. 2006; 53: 1209-1214.
23. Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology 2003; 229: 3-8.
24. Zwick S, Brix G, Tofts PS, Strecker R, Kopp-Schneider A, Laue H, Semmler W, Kiessling W. Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI. Eur. Radiol. 2010; 20: 432-442.
25. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, Padhani AR. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed. 2002; 15: 132-142.